References
- Karami S, Major JM, Calderon S, McAninch JK. Trends in dextromethorphan cough and cold products: 2000–2015 National Poison Data System intentional abuse exposure calls. Clin Toxicol. 2018 July 03;56:656–63. doi:10.1080/15563650.2017.1416124.
- Romanelli F, Smith KM. Dextromethorphan abuse: clinical effects and management. J Am Pharm Assoc. 2009 Mar-Apr;49:e20–7. doi:10.1331/JAPhA.2009.08091.
- PubChem Compound Summary for CID 5360696, Dextromethorphan. National Center for Biotechnology Information; [accessed 2022 June 16]. https://pubchem.ncbi.nlm.nih.gov/compound/Dextromethorphan
- Schifano F, Chiappini S, Miuli A, Mosca A, Santovito MC, Corkery JM, Guirguis A, Pettorruso M, Di Giannantonio M, Martinotti G. Focus on over-the-counter drugs’ misuse: a systematic review on antihistamines, cough medicines, and decongestants. Front Psychiatry. 2021;12:657397. doi:10.3389/fpsyt.2021.657397.
- Majeed A, Xiong J, Teopiz KM, Ng J, Ho R, Rosenblat JD, Phan L, Cao B, McIntyre RS. Efficacy of dextromethorphan for the treatment of depression: a systematic review of preclinical and clinical trials. Expert Opin Emerg Drugs. 2021 Mar;26:63–74. doi:10.1080/14728214.2021.1898588.
- Sills GJ, Rogawski MA. Mechanisms of action of currently used antiseizure drugs. Neuropharmacology. 2020 May 15;168:107966. doi:10.1016/j.neuropharm.2020.107966.
- Quadir SG, Cottone P, Sabino V. Role of sigma receptors in alcohol addiction. Front Pharmacol. 2019;10:687. doi:10.3389/fphar.2019.00687.
- Anton RF, Myrick H, Wright TM, Latham PK, Baros AM, Waid LR, Randall PK. Gabapentin combined with naltrexone for the treatment of alcohol dependence. Am J Psychiatry. 2011 Jul;168:709–17. doi:10.1176/appi.ajp.2011.10101436.
- Martinak B, Bolis RA, Black JR, Fargason RE, Birur B. Dextromethorphan in cough syrup: the poor man’s psychosis. Psychopharmacol Bull. Sep 15 2017;47:59–63.
- O’malley SS, Krishnan-Sarin S, Farren C, Sinha R, Kreek MJ. Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo-pituitary-adrenocortical axis. Psychopharmacol (Berl). 2002 Feb;160:19–29. doi:10.1007/s002130100919.